CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.

MLA

Boumelha, Jesse, et al. “CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.” Cancer Research, vol. 84, no. 14, July 2024, pp. 2231–46. EBSCOhost, https://doi.org/10.1158/0008-5472.CAN-23-2627.

APA

Boumelha, J., de Castro, A., Bah, N., Cha, H., de Carné Trécesson, S., Rana, S., Tomaschko, M., Anastasiou, P., Mugarza, E., Moore, C., Goldstone, R., East, P., Litchfield, K., Lee, S.-H., Molina-Arcas, M., & Downward, J. (2024). CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer. Cancer Research, 84(14), 2231–2246. https://doi.org/10.1158/0008-5472.CAN-23-2627

Chicago

Boumelha, Jesse, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, et al. 2024. “CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.” Cancer Research 84 (14): 2231–46. doi:10.1158/0008-5472.CAN-23-2627.